Hoth Therapeutics Inc Ordinary Shares HOTH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HOTH is a good fit for your portfolio.
News
-
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds
-
Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment
-
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
-
Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio
-
Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic
-
Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024
-
Hoth Therapeutics Shares Rise 14% After FDA Clearance for HT-001 Trial Amendments
Trading Information
- Previous Close Price
- $1.19
- Day Range
- $1.15–1.21
- 52-Week Range
- $0.99–4.30
- Bid/Ask
- $1.15 / $1.17
- Market Cap
- $5.72 Mil
- Volume/Avg
- 16,648 / 492,678
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 3
- Website
- https://www.hoththerapeutics.com
Valuation
|
Metric
|
HOTH
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.57 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
HOTH
|
|---|---|
Quick Ratio | 13.69 |
Current Ratio | 13.89 |
Interest Coverage | — |
Quick Ratio
HOTH
Profitability
|
Metric
|
HOTH
|
|---|---|
Return on Assets (Normalized) | −69.03% |
Return on Equity (Normalized) | −80.19% |
Return on Invested Capital (Normalized) | −80.66% |
Return on Assets
HOTH
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qtytfjjylq | Dmc | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gbcsvgn | Nwlfgc | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rkqrvwhz | Jxvhlwv | $99.6 Bil | |
MRNA
| Moderna Inc | Hsmhlqrx | Gmtsn | $38.8 Bil | |
ARGX
| argenx SE ADR | Rqzymhzm | Nfcc | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Btgfbfb | Pts | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fnbjslys | Xfxxnm | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jbgdrzf | Wdmggk | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Scfqtvxqpm | Jsvsfn | $12.4 Bil | |
INCY
| Incyte Corp | Tttyqhmbs | Pzdbb | $11.9 Bil |